Navigation Links
Second in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

ZURICH, July 16 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

REYKJAVIK, Iceland, July 13 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics (Nasdaq: DCGN ) and colleagues from Europe and the United States today report the discovery of a common single-letter variant in the sequence of the human genome (SNP) conferring increased risk of atrial fibr...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follo...

Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study PALO ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-FirstCall/ -- press releas...

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

SAN DIEGO, June 24 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with...

EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health

VIENNA, Austria, and CUXHAVEN, Germany, June 18 /PRNewswire/ -- EUCODIS Bioscience, a company developing, manufacturing, and marketing enzymes and other proteins for the chemical industry, announced today that it has achieved an important milestone in the development of an undisclosed protein ...

HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study

Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the f...

Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials

Both Phase III pivotal trials begin enrollment in May 2009; Reinforces Lilly's commitment to Alzheimer's disease and biotech product research INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will begin enrolling patients this month in two...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

Completion of enrollment keeps Company on track to report primary study results in third quarter of this year ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the second Phase II clinical trial of its trival...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Cl...

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease - PINE BROOK, N.J., April 20 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatenin...

Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients

ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R)...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates o...

Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)

PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines...

Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia

PALO ALTO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced completion of enrollment in the second of two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia. "Completion of enrollment in thi...

Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma

PRINCETON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Ho...

Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- Radius Health ("Radius") announced today that it has raised an additional $15 million to its second institutional financing round, increasing total Series C investment to $82.5 million and the total amount raised since the company's inception to $106.5 mil...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial

- Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen of Bavituximab in Combination With Carboplatin and Paclitaxel - TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical company developing ...

Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound

Pivotal Study to Provide Real-World Dosing Simulation of Lilly's Gamma-Secretase Inhibitor INDIANAPOLIS, Oct. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will begin enrolling patients in a second Phase III study of LY450139, a ga...

NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the t...

Cytopia Commences Second Phase II Study in Brain Cancer

MELBOURNE, Australia, Sept. 4 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma mult...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

Pivotal Study Seeks to Enroll 750 Women at More Than 100 Sites in the U.S. ANN ARBOR, Mich., Sept. 4 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular diso...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

- First Phase 3 data, from BLISS-52 trial, expected by mid-2009 - - Data from second Phase 3 trial, BLISS-76, expected by fall 2009 - ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced it has completed enrollment and initial dosin...

Cardium Reports on Second Quarter 2008 Highlights and Financial Results

SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM ) today reported recent highlights and developments, as well as financial results for its second quarter ended June 30, 2008. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

Successful End of Phase 2 Meeting with the FDA for the Fabry Program and Initiation of Phase 2 Clinical Trial in Pompe are Highlights for the Quarter CRANBURY, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ), a biopharmaceutical compa...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial results for the quarter and six month period ended June 30, 2008 and provided an update on the Company's progress with its product development candidates. The net loss...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

Broad New Patent Granted CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that they have begun a phase 3 study of mipomersen in patients with heterozygo...

Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decomp...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

- Results from Phase II Melanoma Trial Expected in the Fourth Quarter - BRANFORD, Conn., July 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, today reported its financial results for the second quarter of 2008 a...

Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results

BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thu...

Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

MOUNTAIN VIEW, Calif., July 24 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has initiated its second Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acut...

Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebsel...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

Orexigen is the only company with two late-stage product candidates to address a broad spectrum of obesity patients SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) announced today that it has begun randomizing patients in ZB-202, a seco...

Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease

- Dimebon Showed Statistically Significant Benefit Versus Placebo on All Key Efficacy Endpoints in First Pivotal Trial - SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced it has initiated dosing of patients in its second pivotal Phase ...

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration

International Study to Evaluate Efficacy and Safety in Treating a Leading Cause of Blindness LEVERKUSEN, Germany, MONTVILLE, New Jersey and TARRYTOWN, New York, May 8 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) tod...

TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project

SAN DIEGO, May 6 /PRNewswire/ -- TriLink BioTechnologies (TriLink), a leading provider of custom nucleic acid-based compounds, has been awarded a Phase II Small Business Innovation Research (SBIR) grant of approximately $750,000 to continue its investigation of modified dNTPs to improve the fi...

Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology

CEDAR KNOLLS, N.J., April 16 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that additional preclinical in vivo studies using dogs further demonstrate that its proprietary eligen(R) technology enhances the absorption of oral B12. These data confirm in a...
Other Tags
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
(Date:3/28/2015)... Coffee could not only perk you up in the morning ... have found. , They found that those who drank coffee ... fight gum disease. Does coffee, then, help fight gum disease? ... Goldman School of Dental Medicine explored in a study ... of Periodontology. , “This is the first long-term study of ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... game with knights, nature, and peasants. , The ... to Eurogamer. The popularity of these games grew over ...
(Date:3/28/2015)... With more than 4,500 scientists, ... osteoporosis, osteoarthritis and musculoskeletal diseases gathered here for ... the first time in the 17-year history of ... hot-button topic is an emerging non-pharmaceutical protocol for ... principles of Wolff’s law, osteogenic loading at multiples ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The California-based ... package for every customer shopping on UniWigs during the ... also be a big promotion on April Fools’ Day. ... Day is just around the corner. Easter Festival, with ... States, is a major holiday after Christmas. The best ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
Other Contents